ADC Therapeutics SA (NYSE: ADCT) today reported financial results
for the first quarter ended March 31, 2024, and provided business
updates.
“During the first quarter of 2024, we were pleased to see
continued progress from our corporate and capital allocation
strategy focused primarily on hematology with ZYNLONTA® while
advancing our emerging solid tumor pipeline,” said Ameet Mallik,
Chief Executive Officer of ADC Therapeutics. “In hematology, we
delivered sequential ZYNLONTA revenue growth. We were pleased to
announce that our LOTIS-7 study of ZYNLONTA in combination with
bispecifics has successfully cleared the final dosing cohort and
enrollment in Part 2 dose expansion has been initiated.
Additionally, we were encouraged by the initial IIT Phase 2 data
with ZYNLONTA in MZL which supports potential expansion in MZL and
contributes to the overall ZYNLONTA growth strategy in NHL. With
multiple potential value-generating catalysts ahead this year
including expected completion of enrollment in LOTIS-5, expansion
of LOTIS-7 and initial read of ADCT-601 in AXL, I am excited about
our prospects for continued progress in 2024.”
Recent Highlights and
Developments
ZYNLONTA® (loncastuximab
tesirine-lpyl)
- ZYNLONTA generated product net sales of $17.8 million in the
first quarter of 2024, representing a 7% increase over the fourth
quarter of 2023 and a 6% decrease over the first quarter of 2023.
Sequential quarter-over-quarter growth in the first quarter of 2024
continued, with sales volume increasing in both community and
academic settings. The year-over-year net sales decline reflected
higher gross-to-net deductions and lower volume, partially offset
by a higher price.
Hematology Pipeline
- LOTIS-5: The Phase
3 confirmatory trial for ZYNLONTA in combination with rituximab in
patients with 2L+ diffuse large B-cell lymphoma (DLBCL) continues
to see accelerated enrollment. The Company expects to complete
enrollment of this trial in 2024.
- LOTIS-7: On April
4, 2024, the Company announced the completion of dose escalation in
LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA
in combination with bispecific antibodies glofitamab or
mosunetuzumab in heavily pre-treated patients with
relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). In the
dose escalation portion (Part 1) of LOTIS-7, no dose-limiting
toxicities (DLTs), no or low-grade cytokine release syndrome (CRS)
and no immune effector cell-associated neurotoxicity syndrome
(ICANS) were observed across all patients when ZYNLONTA was
administered in combination with glofitamab or mosunetuzumab.
Additionally, after the first investigator assessment, evidence of
anti-tumor activity (complete response or partial response) was
observed among the majority of patients, with mixed histologies
including r/r DLBCL, follicular lymphoma (FL) and marginal zone
lymphoma (MZL). In addition, as of April 19, 2024, initial safety
findings showed that the majority of CRS events seen were grade 1
(6 out of 18 patients) or grade 2 (2 of 18 patients, 11%), with no
CRS greater than grade 2 observed in either combination arm.
Furthermore, all grade 2 events responded to
Tocilizumab/corticosteroids with no requirement for pressors or ICU
management. Based on the data from Part 1, all three dose levels
(90, 120 and 150 µg/kg) have now been cleared and enrollment in
Part 2 dose expansion has been initiated with ZYNLONTA administered
in combination with glofitamab at the 120 µg/kg and 150 µg/kg dose
levels in 2L+ DLBCL patients.
- Investigator-Initiated
Trial: As announced by the Company today, May 6, 2024,
initial data from an investigator-initiated Phase 2 clinical trial
evaluating ZYNLONTA for the treatment of relapsed/refractory (r/r)
MZL were presented at the Lymphoma Research Foundation’s 2024
Marginal Zone Lymphoma Scientific Workshop by the trial’s lead
investigator. The 50-patient single-arm, open-label Phase 2
multicenter study is currently being conducted at the Sylvester
Comprehensive Cancer Center at University of Miami and City of
Hope, and led by Izidore Lossos, MD, Professor, Director, Lymphoma
Program at the Sylvester Comprehensive Cancer Center, University of
Miami. This study is evaluating the safety and efficacy of ZYNLONTA
in patients with r/r MZL previously treated with ≥1 line of
systemic therapy (ClincalTrials.gov identifier: NCT05296070). As of
the data cutoff date of March 30, 2024, 15 patients were evaluable.
Of these 15 patients evaluated, 13 achieved a complete response
(CR) and one patient achieved a partial response (PR). In this
study, ZYNLONTA was generally well tolerated and the safety profile
was consistent with the known profile, with two patient
discontinuations. All patients who achieved responses had
maintained them at the time of the data cutoff with the longest
responder reaching approximately 20 months.
Solid Tumor Pipeline
- ADCT-601 (targeting
AXL): The Phase 1b trial studying ADCT-601 targeting AXL
continues enrolling patients in the pancreatic cancer monotherapy
arm, optimizing dose and schedule. The ongoing
dose-optimization/expansion phase is comprised of a monotherapy arm
including patients with sarcoma, pancreatic cancer and
AXL-expressing non-small cell lung cancer (NSCLC) and a combination
arm with gemcitabine in patients with sarcoma and pancreatic
cancer.
- Early-stage
pipeline: On April 9, 2024, the Company hosted a virtual
Research Investor Event during which details were shared on
strategy and recent business updates as well as the Company’s novel
exatecan-based ADC platform. The Company provided details on its
four lead candidates – targeting Claudin-6, NaPi2b, PSMA and ASCT2
– which have a differentiated profile based on a novel, proprietary
linker approach to tracelessly release exatecan and a high
therapeutic index. The Company’s NaPi2b and Claudin-6 targeting
ADCs are in IND-enabling studies and PSMA and ASCT2 targeting ADCs
are in drug candidate selection stage, expected to complete this
year. Preclinical data on the Claudin-6 and NaPi2b programs were
shared in presentations at the AACR Annual Meeting 2024 which
demonstrated that each was well tolerated with potent and specific
in vitro and in vivo anti-tumor activity.
Upcoming Expected
Milestones
ZYNLONTA
- Achieve commercial brand
profitability in 2024
- LOTIS-5: Complete enrollment in 2H
2024
- LOTIS-7: Part 2 enrollment complete
with initial efficacy/safety update in 2H 2024; full/mature data in
1H 2025
- Investigator-initiated trial in r/r
FL: The study is being expanded to 100 patients in a multicenter
clinical trial. Updates are anticipated at medical meetings in
2024/2025.
- Investigator-initiated trial in r/r
MZL: The study is designed to enroll 50 patients in a multicenter
clinical trial. Further updates are anticipated at medical meetings
in 2024/2025.
Pipeline
ADCT-601 (targeting AXL)
- Additional data updates from the
Phase 1 study in patients with sarcoma, pancreatic cancer and NSCLC
in 2H 2024
ADCT-602 (targeting CD22)
- Additional data from the Phase 1
study in 2H 2024
Preclinical
- Advancing a broad portfolio of
investigational ADCs for solid tumor indications
First Quarter 2024 Financial
Results
Cash and Cash Equivalents
Cash and cash equivalents were $234.3 million as
of March 31, 2024, compared to $278.6 million as of December 31,
2023. The Company currently expects its cash runway to extend into
the fourth quarter of 2025.
Product Revenues
Net product revenues were $17.8 million for the first quarter
2024, compared to $19.0 million for the first quarter 2023. Net
product revenues are for U.S. sales of ZYNLONTA. The decrease was
primarily due to higher gross-to-net deductions and lower volume,
partially offset by a higher price.
Research and Development (R&D)
Expenses
R&D expenses were $25.7 million for the
first quarter 2024, compared to $38.4 million for the first quarter
2023. R&D expenses decreased due to less investment in
camidanlumab tesirine (Cami), as well as productivity initiatives
and focused investment toward prioritized development programs. The
decrease in R&D expenses related to Cami was primarily due to
our evaluation of FDA feedback and decision to stop the
program.
R&D expenses for the first quarter 2024 also
decreased due to lower share-based compensation expense resulting
from fluctuations in the share price and award forfeitures in
connection with terminations.
Selling and Marketing (S&M) Expenses
S&M expenses were $11.4 million for the
first quarter 2024, compared to $15.4 million for the first quarter
2023. The decrease in S&M expenses was primarily due to lower
spend on marketing and advertising, lower wages and benefits, as
well as lower share-based compensation expense resulting from
fluctuations in the share price and award forfeitures in connection
with terminations.
General & Administrative (G&A)
Expenses
G&A expenses were $12.0 million for the
first quarter 2024, compared to $15.5 million for the first quarter
2023. The decrease in G&A expenses was primarily due to lower
share-based compensation expense resulting from fluctuations in the
share price and award forfeitures in connection with terminations,
lower wages and benefits and insurance costs, partially offset by
higher professional fees including audit and legal fees.
Net Loss and Adjusted Net
Loss
Net loss was $46.6 million, or a net loss of
$0.56 per basic and diluted share, for the first quarter of 2024
and a net loss of $59.4 million, or a net loss of $0.73 per basic
and diluted share for the first quarter of 2023. The decrease in
net loss is primarily due to lower operating expenses, partially
offset by changes in the fair value of our Deerfield warrant
obligation and higher accretion of our deferred royalty
obligation.
Adjusted net loss, which is a non-GAAP financial
measure, was $31.1 million, or an adjusted net loss of $0.38 per
basic and diluted share for the first quarter 2024 and $41.8
million, or an adjusted net loss of $0.52 per basic and diluted
share for the first quarter 2023. The decrease in adjusted net loss
for the quarter primarily reflects our lower operating
expenses.
Conference Call Details
ADC Therapeutics management will host a conference call and live
audio webcast to discuss first quarter 2024 financial results and
provide a company update today at 8:30 a.m. Eastern Time. To access
the conference call, please register here. Registrants will receive
the dial-in number and unique PIN. It is recommended that you join
10 minutes before the event, though you may pre-register at any
time. A live webcast of the call will be available under “Events
& Presentations” in the Investors section of the ADC
Therapeutics website at ir.adctherapeutics.com. The archived
webcast will be available for 30 days following the call.
About ZYNLONTA® (loncastuximab
tesirine-lpyl)
ZYNLONTA® is a CD19-directed antibody drug
conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is
internalized by the cell, where enzymes release a
pyrrolobenzodiazepine (PBD) payload. The potent payload binds to
DNA minor groove with little distortion, remaining less visible to
DNA repair mechanisms. This ultimately results in cell cycle arrest
and tumor cell death.
The U.S. Food and Drug Administration (FDA) and
the European Medicines Agency (EMA) have approved ZYNLONTA
(loncastuximab tesirine-lpyl) for the treatment of adult patients
with relapsed or refractory (r/r) large B-cell lymphoma after two
or more lines of systemic therapy, including diffuse large B-cell
lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from
low-grade lymphoma and also high-grade B-cell lymphoma. The trial
included a broad spectrum of heavily pre-treated patients (median
three prior lines of therapy) with difficult-to-treat disease,
including patients who did not respond to first-line therapy,
patients refractory to all prior lines of therapy, patients with
double/triple hit genetics and patients who had stem cell
transplant and CAR-T therapy prior to their treatment with
ZYNLONTA. This indication is approved by the FDA under accelerated
approval and in the European Union under conditional approval based
on overall response rate and continued approval for this indication
may be contingent upon verification and description of clinical
benefit in a confirmatory trial. Please see full prescribing
information including important safety information about ZYNLONTA
at www.ZYNLONTA.com.
ZYNLONTA is also being evaluated as a
therapeutic option in combination studies in other B-cell
malignancies and earlier lines of therapy.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a
commercial-stage global leader and pioneer in the field of antibody
drug conjugates (ADCs). The Company is advancing its proprietary
ADC technology to transform the treatment paradigm for patients
with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA
(loncastuximab tesirine-lpyl) received accelerated approval by the
FDA and conditional approval from the European Commission for the
treatment of relapsed or refractory diffuse large B-cell lymphoma
after two or more lines of systemic therapy. ZYNLONTA is also in
development in combination with other agents and in earlier lines
of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple
ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle),
Switzerland and has operations in London and New Jersey. For more
information, please visit https://adctherapeutics.com/ and follow
the Company on LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Use of Non-GAAP Financial
Measures
In addition to financial information prepared in
accordance with U.S. Generally Accepted Accounting Principles
(GAAP), this document also contains certain non-GAAP financial
measures based on management’s view of performance including:
- Adjusted total operating
expenses
- Adjusted net loss
- Adjusted net loss per share
Management uses such measures internally when
monitoring and evaluating our operational performance, generating
future operating plans and making strategic decisions regarding the
allocation of capital. We believe that these adjusted financial
measures provide useful information to investors and others in
understanding and evaluating our operating results in the same
manner as our management and facilitate operating performance
comparability across both past and future reporting periods. These
non-GAAP measures have limitations as financial measures and should
be considered in addition to, and not in isolation or as a
substitute for, the information prepared in accordance with GAAP.
When preparing these supplemental non-GAAP measures, management
typically excludes certain GAAP items that management does not
believe are indicative of our ongoing operating performance.
Furthermore, management does not consider these GAAP items to be
normal, recurring cash operating expenses; however, these items may
not meet the GAAP definition of unusual or non-recurring items.
Since non-GAAP financial measures do not have standardized
definitions and meanings, they may differ from the non-GAAP
financial measures used by other companies, which reduces their
usefulness as comparative financial measures. Because of these
limitations, you should consider these adjusted financial measures
alongside other GAAP financial measures.
The following items are excluded from adjusted
total operating expenses:
Shared-Based Compensation Expense: We exclude
share-based compensation expense from our adjusted financial
measures because share-based compensation expense, which is
non-cash, fluctuates from period to period based on factors that
are not within our control, such as our stock price on the dates
share-based grants are issued. Share-based compensation expense has
been, and will continue to be for the foreseeable future, a
recurring expense in our business and an important part of our
compensation strategy.
The following items are excluded from adjusted
net loss and adjusted net loss per share:
Shared-Based Compensation Expense: We exclude
share-based compensation expense from our adjusted financial
measures because share-based compensation expense, which is
non-cash, fluctuates from period to period based on factors that
are not within our control, such as our stock price on the dates
share-based grants are issued. Share-based compensation expense has
been, and will continue to be for the foreseeable future, a
recurring expense in our business and an important part of our
compensation strategy.
Certain Other Items: We exclude certain other
significant items that we believe do not represent the performance
of our business, from our adjusted financial measures. Such items
are evaluated by management on an individual basis based on both
quantitative and qualitative aspects of their nature. While not
all-inclusive, examples of certain other significant items excluded
from our adjusted financial measures would be: changes in the fair
value of warrant obligations and the effective interest expense
associated with the senior secured term loan facility and the
effective interest expense and cumulative catch-up adjustments
associated with the deferred royalty obligation under the royalty
purchase agreement with HealthCare Royalty Partners.
See the attached Reconciliation of GAAP Measures
to Non-GAAP Measures for explanations of the amounts excluded and
included to arrive at the non-GAAP financial measures.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. In some cases you
can identify forward-looking statements by terminology such as
“may”, “will”, “should”, “would”, “expect”, “intend”, “plan”,
“anticipate”, “believe”, “estimate”, “predict”, “potential”,
“seem”, “seek”, “future”, “continue”, or “appear” or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: the success of the Company’s
updated corporate strategy; the expected cash runway into the
beginning of Q4 2025, the effectiveness of the new commercial
go-to-market strategy, competition from new technologies, the
Company’s ability to grow ZYNLONTA® revenue in the United States;
Swedish Orphan Biovitrum AB’s (Sobi®) ability to successfully
commercialize ZYNLONTA® in the European Economic Area and market
acceptance, adequate reimbursement coverage, and future revenue
from the same; approval by the NMPA of the BLA for ZYNLONTA® in
China submitted by Overland ADCT BioPharma and future revenue from
the same, our strategic partners’, including Mitsubishi Tanabe
Pharma Corporation, ability to obtain regulatory approval for
ZYNLONTA® in foreign jurisdictions, and the timing and amount of
future revenue and payments to us from such partnerships; the
timing and results of the Company’s or its partners’ research and
development projects or clinical trials including LOTIS 5 and 7,
ADCT 601 and 602 as well as early research in certain solid tumors
with different targets, linkers and payloads; the timing and
results of the University of Miami’s investigator-initiated trials
in FL and MZL, potential regulatory and/or compendia strategy and
the future opportunity; the timing and outcome of regulatory
submissions for the Company’s products or product candidates;
actions by the FDA or foreign regulatory authorities; projected
revenue and expenses; the Company’s indebtedness, including
Healthcare Royalty Management and Blue Owl and Oaktree facilities,
and the restrictions imposed on the Company’s activities by such
indebtedness, the ability to comply with the terms of the various
agreements and repay such indebtedness and the significant cash
required to service such indebtedness; and the Company’s ability to
obtain financial and other resources for its research, development,
clinical, and commercial activities. Additional information
concerning these and other factors that may cause actual results to
differ materially from those anticipated in the forward-looking
statements is contained in the “Risk Factors” section of the
Company's Annual Report on Form 10-K and in the Company's other
periodic and current reports and filings with the U.S. Securities
and Exchange Commission. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this
document.
ADC Therapeutics
SACondensed Consolidated Statements of Operation
(Unaudited)(in thousands, except for share and per
share data)
|
|
For the Three Months Ended March 31, |
|
|
2024 |
|
2023 |
Revenue |
|
|
|
|
Product revenues,
net |
|
$ 17,848 |
|
$ 18,953 |
License revenues
and royalties |
|
205 |
|
39 |
Total
revenue, net |
|
18,053 |
|
18,992 |
Operating
expense |
|
|
|
|
Cost of product sales |
|
(2,510) |
|
27 |
Research and development |
|
(25,735) |
|
(38,375) |
Selling and marketing |
|
(11,390) |
|
(15,351) |
General and administrative |
|
(12,031) |
|
(15,503) |
Total operating
expense |
|
(51,666) |
|
(69,202) |
Loss from
operations |
|
(33,613) |
|
(50,210) |
|
|
|
|
|
Other income
(expense) |
|
|
|
|
Interest income |
|
2,948 |
|
2,175 |
Interest expense |
|
(12,496) |
|
(10,291) |
Other, net |
|
(2,595) |
|
833 |
Total other
expense |
|
(12,143) |
|
(7,283) |
Loss
before income taxes |
|
(45,756) |
|
(57,493) |
Income tax expense |
|
(163) |
|
(518) |
Loss
before equity in net losses of joint venture |
|
(45,919) |
|
(58,011) |
Equity in net losses of joint venture |
|
(687) |
|
(1,363) |
Net
loss |
|
$ (46,606) |
|
$ (59,374) |
|
|
|
|
|
Net loss
per share |
|
|
|
|
Net loss per share, basic and diluted |
|
$ (0.56) |
|
$ (0.73) |
Weighted average shares outstanding, basic and diluted |
|
82,552,322 |
|
80,805,770 |
|
|
|
|
|
ADC Therapeutics
SACondensed Consolidated Balance Sheet
(Unaudited)(in thousands)
|
|
March 31, 2024 |
|
December 31, 2023 |
ASSETS |
|
|
|
|
Current
assets |
|
|
|
|
Cash and cash equivalents |
|
$ 234,285 |
|
$ 278,598 |
Accounts receivable, net |
|
23,186 |
|
25,182 |
Inventory |
|
15,997 |
|
16,177 |
Prepaid expenses and other current assets |
|
16,738 |
|
16,334 |
Total
current assets |
|
290,206 |
|
336,291 |
Non-current assets |
|
|
|
|
Property and equipment, net |
|
5,785 |
|
5,622 |
Operating lease right-of-use assets |
|
10,059 |
|
10,511 |
Interest in joint venture |
|
930 |
|
1,647 |
Other long-term assets |
|
986 |
|
711 |
Total
assets |
|
$ 307,966 |
|
$ 354,782 |
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
Current
liabilities |
|
|
|
|
Accounts payable |
|
$ 14,315 |
|
$ 15,569 |
Accrued expenses and other current liabilities |
|
48,670 |
|
52,101 |
Total
current liabilities |
|
62,985 |
|
67,670 |
|
|
|
|
|
Deferred royalty obligation |
|
310,010 |
|
303,572 |
Senior secured term loans |
|
113,234 |
|
112,730 |
Operating lease liabilities, long-term |
|
9,662 |
|
10,180 |
Other long-term liabilities |
|
6,524 |
|
8,879 |
Total
liabilities |
|
502,415 |
|
503,031 |
|
|
|
|
|
Total
shareholders’ (deficit) equity |
|
(194,449) |
|
(148,249) |
|
|
|
|
|
Total
liabilities and shareholders’ equity |
|
$ 307,966 |
|
$ 354,782 |
ADC Therapeutics
SAReconciliation of GAAP Measures to Non-GAAP
Measures (Unaudited)(in thousands, except for
share and per share data)
|
Three Months Ended March 31, |
(in
thousands) |
2024 |
|
2023 |
|
Change |
|
% Change |
Total
operating expense |
$ (51,666) |
|
$ (69,202) |
|
$ 17,536 |
|
(25)% |
Adjustments: |
|
|
|
|
|
|
|
Share-based
compensation expense (i) |
158 |
|
8,074 |
|
(7,916) |
|
(98)% |
Adjusted
total operating expenses |
$
(51,508) |
|
$ (61,128) |
|
$
9,620 |
|
(16)% |
|
|
Three Months Ended March 31, |
in
thousands (except for share and per share data) |
|
2024 |
|
2023 |
Net
loss |
|
$ (46,606) |
|
$ (59,374) |
Adjustments: |
|
|
|
|
Share-based
compensation expense (i) |
|
158 |
|
8,074 |
Deerfield
warrants obligation, change in fair value expense (income)
(ii) |
|
3,068 |
|
(616) |
Effective
interest expense on senior secured term loan facility (iii) |
|
4,403 |
|
4,540 |
Deferred royalty
obligation interest expense (iv) |
|
8,093 |
|
5,746 |
Deferred royalty
obligation cumulative catch-up adjustment income (iv) |
|
(263) |
|
(129) |
Adjusted
net loss |
|
$ (31,147) |
|
$ (41,759) |
|
|
|
|
|
Net loss per
share, basic and diluted |
|
$ (0.56) |
|
$ (0.73) |
Adjustment to net
loss per share, basic and diluted |
|
0.18 |
|
0.21 |
Adjusted
net loss per share, basic and diluted |
|
$
(0.38) |
|
$
(0.52) |
Weighted average
shares outstanding, basic and diluted |
|
82,552,322 |
|
80,805,770 |
- Share-based compensation expense represents the cost of equity
awards issued to our directors, management and employees. The fair
value of awards is computed at the time the award is granted, and
is recognized over the requisite service period less actual
forfeitures by a charge to the statement of operations and a
corresponding increase in additional paid-in capital within equity.
These accounting entries have no cash impact.
- Change in the fair value of the Deerfield warrant obligation
results from the valuation at the end of each accounting period.
There are several inputs to these valuations, but those most likely
to result in significant changes to the valuations are changes in
the value of the underlying instrument (i.e., changes in the price
of our common shares) and changes in expected volatility in that
price. These accounting entries have no cash impact.
- Effective interest expense on senior secured term loans relates
to the increase in the value of our loans in accordance with the
amortized cost method.
- Deferred royalty obligation interest expense relates to the
accretion expense on our deferred royalty obligation pursuant to
the royalty purchase agreement with HCR and cumulative catch-up
adjustments related to changes in the expected payments to HCR
based on a periodic assessment of our underlying revenue
projections.
CONTACT:
Investors and MediaNicole RileyADC
TherapeuticsNicole.Riley@adctherapeutics.com +1
862-926-9040
(1) See reconciliation of GAAP measures to non-GAAP measures in
accompanying financial tables
ADC Therapeutics (NYSE:ADCT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
ADC Therapeutics (NYSE:ADCT)
Gráfica de Acción Histórica
De May 2023 a May 2024